User menu

Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma

Bibliographic reference Finisguerra, Veronica ; Prenen, Hans ; Mazzone, Massimiliano. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. In: Oncogene : including Oncogene Reviews, Vol. /, no./, p. / (/)
Permanent URL http://hdl.handle.net/2078.1/170506
  1. Giordano S., Ponzetto C., Renzo M. F. Di, Cooper C. S., Comoglio P. M., Tyrosine kinase receptor indistinguishable from the c-met protein, 10.1038/339155a0
  2. Komada Masayuki, Hatsuzawa Kiyotaka, Shibamoto Sayumi, Ito Fumiaki, Nakayama Kazuhisa, Kitamura Naomi, Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin, 10.1016/0014-5793(93)80958-w
  3. Bottaro D., Rubin J., Faletto D., Chan A., Kmiecik T., Vande Woude G., Aaronson S., Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, 10.1126/science.1846706
  4. Trusolino Livio, Bertotti Andrea, Comoglio Paolo M., MET signalling: principles and functions in development, organ regeneration and cancer, 10.1038/nrm3012
  5. Lyon M, J Biol Chem, 269, 11216 (1994)
  6. Mars WM, Am J Pathol, 143, 949 (1993)
  7. Matsumoto K., Nakamura T., Emerging Multipotent Aspects of Hepatocyte Growth Factor, 10.1093/oxfordjournals.jbchem.a021283
  8. Galimi F., Cottone E., Vigna E., Arena N., Boccaccio C., Giordano S., Naldini L., Comoglio P. M., Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function, 10.4049/jimmunol.166.2.1241
  9. Kurz Steffen M., Diebold Sandra S., Hieronymus Thomas, Gust Tatjana C., Bartunek Petr, Sachs Martin, Birchmeier Walter, Zenke Martin, The impact of c-met/scatter factor receptor on dendritic cell migration, 10.1002/1521-4141(200207)32:7<1832::aid-immu1832>3.0.co;2-2
  10. Ovali E, Haematologica, 85, 464 (2000)
  11. Voort Robbert van der, Taher Taher E.I., Keehnen Robert M.J., Smit Lia, Groenink Martijn, Pals Steven T., Paracrine Regulation of Germinal Center B Cell Adhesion through the c-Met–Hepatocyte Growth Factor/Scatter Factor Pathway, 10.1084/jem.185.12.2121
  12. Schmidt Claudia, Bladt Friedhelm, Goedecke Stefanie, Brinkmann Volker, Zschiesche Wolfgang, Sharpe Melanie, Gherardi Ermanno, Birchmeler Carmen, Scatter factor/hepatocyte growth factor is essential for liver development, 10.1038/373699a0
  13. Uehara Yoshihiko, Minowa Osamu, Mori Chisato, Shiota Kohei, Kuno Junko, Noda Tetsuo, Kitamura Naomi, Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor, 10.1038/373702a0
  14. Ueno Masaya, Lee Lydia K., Chhabra Akanksha, Kim Yeon Joo, Sasidharan Rajkumar, Van Handel Ben, Wang Ying, Kamata Masakazu, Kamran Paniz, Sereti Konstantina-Ioanna, Ardehali Reza, Jiang Meisheng, Mikkola Hanna K.A., c-Met-Dependent Multipotent Labyrinth Trophoblast Progenitors Establish Placental Exchange Interface, 10.1016/j.devcel.2013.10.019
  15. Birchmeier Carmen, Gherardi Ermanno, Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase, 10.1016/s0962-8924(98)01359-2
  16. Bladt Friedhelm, Riethmacher Dieter, Isenmann Stefan, Aguzzi Adriano, Birchmeier Carmen, Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud, 10.1038/376768a0
  17. Maina F., Hilton M. C., Ponzetto C., Davies A. M., Klein R., Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons, 10.1101/gad.11.24.3341
  18. Gallo S., Sala V., Gatti S., Crepaldi T., Cellular and molecular mechanisms of HGF/Met in the cardiovascular system, 10.1042/cs20150502
  19. Huh C.-G., Factor V. M., Sanchez A., Uchida K., Conner E. A., Thorgeirsson S. S., Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair, 10.1073/pnas.0306068101
  20. Matsumoto Kunio, Nakamura Toshikazu, Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases, 10.1046/j.1523-1755.2001.00717.x
  21. Nakamura Toshikazu, Nishizawa Tsutomu, Hagiya Mitchio, Seki Tatsuya, Shimonishi Manabu, Sugimura Atsushi, Tashiro Kosuke, Shimizu Shin, Molecular cloning and expression of human hepatocyte growth factor, 10.1038/342440a0
  22. Ueda H, A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats, 10.1016/s0008-6363(01)00272-3
  23. Liu Y., Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action, 10.1152/ajprenal.00451.2003
  24. Chang H., Nagao T., Ichikawa N., Kawamoto T., Nakamura T., Kurokawa K., Asano S., Katoh T., Blood Hepatocyte Growth Factor Levels in Chronic Renal Failure Patients, 10.1159/000188032
  25. Shiota Goshi, Okano Jun-Ichi, Kawasaki Hironaka, Kawamoto Tomokazu, Nakamura Toshikazu, Serum hepatocyte growth factor levels in liver diseases: Clinical implications, 10.1002/hep.1840210119
  26. Takada Shingo, Namiki Mikio, Takahara Shiro, Matsumiya Kiyomi, Kondoh Nobuyuki, Kokado Yukito, Matsumoto Kunio, Nakamura Toshikazu, Okuyama Akihiko, Serum HGF levels in acute renal rejection after living related renal transplantation, 10.1111/j.1432-2277.1996.tb00870.x
  27. Tomiya Tomoaki, Tani Masayoshi, Yamada Shinwa, Hayashi Shigeki, Umeda Noritsugu, Fujiwara Kenji, Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients, 10.1016/0016-5085(92)91186-8
  28. Chmielowiec Jolanta, Borowiak Malgorzata, Morkel Markus, Stradal Theresia, Munz Barbara, Werner Sabine, Wehland Jürgen, Birchmeier Carmen, Birchmeier Walter, c-Met is essential for wound healing in the skin, 10.1083/jcb.200701086
  29. Cooper Colin S., Park Morag, Blair Donald G., Tainsky Michael A., Huebner Kay, Croce Carlo M., Vande Woude George F., Molecular cloning of a new transforming gene from a chemically transformed human cell line, 10.1038/311029a0
  30. Park M., Dean M., Kaul K., Braun M. J., Gonda M. A., Vande Woude G., Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors., 10.1073/pnas.84.18.6379
  31. Corso S., Giordano S., Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective, 10.1158/2159-8290.cd-13-0040
  32. Soman N. R., Correa P., Ruiz B. A., Wogan G. N., The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions., 10.1073/pnas.88.11.4892
  33. Peters Solange, Adjei Alex A., MET: a promising anticancer therapeutic target, 10.1038/nrclinonc.2012.71
  34. Schmidt Laura, Duh Fuh-Mei, Chen Fan, Kishida Takeshi, Glenn Gladys, Choyke Peter, Scherer Stephen W., Zhuang Zhenping, Lubensky Irina, Dean Michael, Allikmets Rando, Chidambaram Abi, Bergerheim Ulf R., Feltis J. Timothy, Casadevall Carme, Zamarron Agustin, Bernues Marta, Richard Stephane, Lips C.J.M., Walther McClellan M., Tsui Lap-Chee, Geil Laura, Orcutt Mary Lou, Stackhouse Thomas, Lipan Jami, Slife Leah, Brauch Hiltrud, Decker Jochen, Niehans Gloria, Hughson Michael D., Moch Holger, Storkel Stephan, Lerman Michael I., Linehan W. Marston, Zbar Berton, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, 10.1038/ng0597-68
  35. Schmidt Laura, Junker Kerstin, Nakaigawa Noboru, Kinjerski Tracy, Weirich Gregor, Miller Maria, Lubensky Irina, Neumann Hartmut PH, Brauch Hiltrud, Decker Johann, Vocke Cathy, Brown James A, Jenkins Robert, Richard Stephane, Bergerheim Ulf, Gerrard Bernard, Dean Michael, Linehan W Marston, Zbar Berton, Novel mutations of the MET proto-oncogene in papillary renal carcinomas, 10.1038/sj.onc.1202547
  36. Ivan Mircea, Bond Jane A, Prat Maria, Comoglio Paolo Maria, Wynford-Thomas David, Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells, 10.1038/sj.onc.1201083
  37. Hwang C.-I., Matoso A., Corney D. C., Flesken-Nikitin A., Korner S., Wang W., Boccaccio C., Thorgeirsson S. S., Comoglio P. M., Hermeking H., Nikitin A. Y., Wild-type p53 controls cell motility and invasion by dual regulation of MET expression, 10.1073/pnas.1017536108
  38. Stein Ulrike, Walther Wolfgang, Arlt Franziska, Schwabe Holger, Smith Janice, Fichtner Iduna, Birchmeier Walter, Schlag Peter M, MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis, 10.1038/nm.1889
  39. Nasser Mohd W., Datta Jharna, Nuovo Gerard, Kutay Huban, Motiwala Tasneem, Majumder Sarmila, Wang Bo, Suster Saul, Jacob Samson T., Ghoshal Kalpana, Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer : SUPPRESSION OF TUMORIGENIC PROPERTY OF LUNG CANCER CELLS AND THEIR SENSITIZATION TO DOXORUBICIN-INDUCED APOPTOSIS BY miR-1, 10.1074/jbc.m804788200
  40. Migliore C., Martin V., Leoni V. P., Restivo A., Atzori L., Petrelli A., Isella C., Zorcolo L., Sarotto I., Casula G., Comoglio P. M., Columbano A., Giordano S., MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer, 10.1158/1078-0432.ccr-11-1699
  41. Zhu Xiaopei, Humphrey Peter A, Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma, 10.1016/s0090-4295(00)00795-0
  42. Seidel Carina, Børset Magne, Hjorth-Hansen Henrik, Sundan Anders, Waage Anders, Role of hepatocyte growth factor and its receptorc-met in multiple myeloma, 10.1007/bf02821933
  43. Koochekpour S, Cancer Res, 57, 5391 (1997)
  44. Børset Magne, Lien Egil, Espevik Terje, Helseth Eirik, Waage Anders, Sundan Anders, Concomitant Expression of Hepatocyte Growth Factor/Scatter Factor and the Receptor c-MET in Human Myeloma Cell Lines, 10.1074/jbc.271.40.24655
  45. Kentsis Alex, Reed Casie, Rice Kim L, Sanda Takaomi, Rodig Scott J, Tholouli Eleni, Christie Amanda, Valk Peter J M, Delwel Ruud, Ngo Vu, Kutok Jeffery L, Dahlberg Suzanne E, Moreau Lisa A, Byers Richard J, Christensen James G, Woude George Vande, Licht Jonathan D, Kung Andrew L, Staudt Louis M, Look A Thomas, Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia, 10.1038/nm.2819
  46. Cortner J, EXS, 74, 89 (1995)
  47. Ma Jihong, DeFrances Marie C., Zou Chunbin, Johnson Carla, Ferrell Robert, Zarnegar Reza, Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer, 10.1172/jci36640
  48. Tuck AB, Am J Pathol, 148, 225 (1996)
  49. Abounader R., Ranganathan S., Kim B. Y. S., Nichols C., Laterra J., Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma : c-met induction by SF/HGF, 10.1046/j.1471-4159.2001.00158.x
  50. Zhang Y.-W., Su Y., Volpert O. V., Woude G. F. V., Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation, 10.1073/pnas.2135113100
  51. Rabinovitz Isaac, Mercurio Arthur M., The integrin α6β4 and the biology of carcinoma, 10.1139/o96-087
  52. Trusolino Livio, Bertotti Andrea, Comoglio Paolo M, A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth, 10.1016/s0092-8674(01)00567-0
  53. Misra Suniti, Heldin Paraskevi, Hascall Vincent C., Karamanos Nikos K., Skandalis Spyros S., Markwald Roger R., Ghatak Shibnath, Hyaluronan-CD44 interactions as potential targets for cancer therapy : Targeting CD44 variants in tumors, 10.1111/j.1742-4658.2011.08071.x
  54. Giordano Silvia, Corso Simona, Conrotto Paolo, Artigiani Stefania, Gilestro Giorgio, Barberis Davide, Tamagnone Luca, Comoglio Paolo M., The Semaphorin 4D receptor controls invasive growth by coupling with Met, 10.1038/ncb843
  55. Valente G, Cell Oncol, 31, 423 (2009)
  56. Chen C.-T., Kim H., Liska D., Gao S., Christensen J. G., Weiser M. R., MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells, 10.1158/1535-7163.mct-11-0754
  57. Engelman J. A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J. O., Lindeman N., Gale C.-M., Zhao X., Christensen J., Kosaka T., Holmes A. J., Rogers A. M., Cappuzzo F., Mok T., Lee C., Johnson B. E., Cantley L. C., Janne P. A., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, 10.1126/science.1141478
  58. Sennino Barbara, Ishiguro-Oonuma Toshina, Wei Ying, Naylor Ryan M., Williamson Casey W., Bhagwandin Vikash, Tabruyn Sebastien P., You Weon-Kyoo, Chapman Harold A., Christensen James G., Aftab Dana T., McDonald Donald M., Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors, 10.1158/2159-8290.cd-11-0240
  59. Straussman Ravid, Morikawa Teppei, Shee Kevin, Barzily-Rokni Michal, Qian Zhi Rong, Du Jinyan, Davis Ashli, Mongare Margaret M., Gould Joshua, Frederick Dennie T., Cooper Zachary A., Chapman Paul B., Solit David B., Ribas Antoni, Lo Roger S., Flaherty Keith T., Ogino Shuji, Wargo Jennifer A., Golub Todd R., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, 10.1038/nature11183
  60. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., Uehara H., Mitsudomi T., Yatabe Y., Nakamura T., Sone S., Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations, 10.1158/0008-5472.can-08-1643
  61. Kumai Takumi, Matsuda Yoshinari, Ohkuri Takayuki, Oikawa Kensuke, Ishibashi Kei, Aoki Naoko, Kimura Shoji, Harabuchi Yasuaki, Celis Esteban, Kobayashi Hiroya, c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma, 10.4161/2162402x.2014.976077
  62. Bussolino F., Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth, 10.1083/jcb.119.3.629
  63. Michieli Paolo, Mazzone Massimiliano, Basilico Cristina, Cavassa Silvia, Sottile Antonino, Naldini Luigi, Comoglio Paolo M, Targeting the tumor and its microenvironment by a dual-function decoy Met receptor, 10.1016/j.ccr.2004.05.032
  64. Silvagno F., Follenzi A., Arese M., Prat M., Giraudo E., Gaudino G., Camussi G., Comoglio P. M., Bussolino F., In Vivo Activation of met Tyrosine Kinase by Heterodimeric Hepatocyte Growth Factor Molecule Promotes Angiogenesis, 10.1161/01.atv.15.11.1857
  65. Finisguerra Veronica, Di Conza Giusy, Di Matteo Mario, Serneels Jens, Costa Sandra, Thompson A. A. Roger, Wauters Els, Walmsley Sarah, Prenen Hans, Granot Zvi, Casazza Andrea, Mazzone Massimiliano, MET is required for the recruitment of anti-tumoural neutrophils, 10.1038/nature14407
  66. Wojta J, Lab Invest, 79, 427 (1999)
  67. Comoglio Paolo M., Giordano Silvia, Trusolino Livio, Drug development of MET inhibitors: targeting oncogene addiction and expedience, 10.1038/nrd2530
  68. Matsumoto Kunio, Nakamura Toshikazu, Mechanisms and significance of bifunctional NK4 in cancer treatment, 10.1016/j.bbrc.2005.05.131
  69. Matsumoto Kunio, NK4 gene therapy targeting HGF-Met and angiogenesis, 10.2741/2813
  70. Camussi G, J Immunol, 158, 1302 (1997)
  71. Kobayashi H., Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment, 10.1182/blood-2005-09-012807
  72. Liu Y, Wilkinson FL, Kirton JP, Jeziorska M, Iizasa H, Sai Y, Nakashima E, Heagerty AM, Canfield AE, Alexander MY, Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development, 10.1002/path.2155
  73. Yen B. Linju, Yen Men-Luh, Hsu Pei-Ju, Liu Ko-Jiunn, Wang Chia-Jen, Bai Chyi-Huey, Sytwu Huey-Kang, Multipotent Human Mesenchymal Stromal Cells Mediate Expansion of Myeloid-Derived Suppressor Cells via Hepatocyte Growth Factor/c-Met and STAT3, 10.1016/j.stemcr.2013.06.006
  74. Tesio M., Golan K., Corso S., Giordano S., Schajnovitz A., Vagima Y., Shivtiel S., Kalinkovich A., Caione L., Gammaitoni L., Laurenti E., Buss E. C., Shezen E., Itkin T., Kollet O., Petit I., Trumpp A., Christensen J., Aglietta M., Piacibello W., Lapidot T., Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling, 10.1182/blood-2009-06-230359
  75. Galimi F., Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors, 10.1083/jcb.127.6.1743
  76. Chen Q, Cell Growth Differ, 7, 821 (1996)
  77. Futamatsu H., Hepatocyte Growth Factor Ameliorates the Progression of Experimental Autoimmune Myocarditis: A Potential Role for Induction of T Helper 2 Cytokines, 10.1161/01.res.0000163016.52653.2e
  78. Nakamura Teruya, Mizuno Shinya, Matsumoto Kunio, Sawa Yoshiki, Matsuda Hikaru, Nakamura Toshikazu, Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF, 10.1172/jci10226
  79. Okunishi Katsuhide, Dohi Makoto, Fujio Keishi, Nakagome Kazuyuki, Tabata Yasuhiko, Okasora Takahiro, Seki Makoto, Shibuya Mihoko, Imamura Mitsuru, Harada Hiroaki, Tanaka Ryoichi, Yamamoto Kazuhiko, Hepatocyte Growth Factor Significantly Suppresses Collagen-Induced Arthritis in Mice, 10.4049/jimmunol.179.8.5504
  80. Kuroiwa Takanori, Kakishita Eizo, Hamano Teruaki, Kataoka Yasuro, Seto Yoshifumi, Iwata Nobuo, Kaneda Yasufumi, Matsumoto Kunio, Nakamura Toshikazu, Ueki Takahiro, Fujimoto Jiro, Iwasaki Tsuyoshi, Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function, 10.1172/jci11808
  81. Gong R., Anti-Inflammatory Effect of Hepatocyte Growth Factor in Chronic Kidney Disease: Targeting the Inflamed Vascular Endothelium, 10.1681/asn.2006020185
  82. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y, Okamoto M, Nakamura T, Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease., 10.1172/jci1709
  83. Oh K., Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model, 10.1152/ajpgi.00438.2004
  84. Mizuno S, FASEB J, 19, 580 (2005)
  85. Yamaura K., Suppression of Acute and Chronic Rejection by Hepatocyte Growth Factor in a Murine Model of Cardiac Transplantation: Induction of Tolerance and Prevention of Cardiac Allograft Vasculopathy, 10.1161/01.cir.0000143052.45956.71
  86. Ito Wataru, Kanehiro Arihiko, Matsumoto Kunio, Hirano Atsushi, Ono Katsuichiro, Maruyama Hiromi, Kataoka Mikio, Nakamura Toshikazu, Gelfand Erwin W., Tanimoto Mitsune, Hepatocyte Growth Factor Attenuates Airway Hyperresponsiveness, Inflammation, and Remodeling, 10.1165/rcmb.2004-0058oc
  87. Okunishi K., Dohi M., Nakagome K., Tanaka R., Mizuno S., Matsumoto K., Miyazaki J.-i., Nakamura T., Yamamoto K., A Novel Role of Hepatocyte Growth Factor as an Immune Regulator through Suppressing Dendritic Cell Function, 10.4049/jimmunol.175.7.4745
  88. Benkhoucha Mahdia, Molnarfi Nicolas, Schneiter Gregory, Walker Paul R, Lalive Patrice H, The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity, 10.1186/1742-2094-10-154
  89. Benkhoucha M., Santiago-Raber M.-L., Schneiter G., Chofflon M., Funakoshi H., Nakamura T., Lalive P. H., Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells, 10.1073/pnas.0912437107
  90. Chen P.-M., Liu K.-J., Hsu P.-J., Wei C.-F., Bai C.-H., Ho L.-J., Sytwu H.-K., Yen B. L., Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2, 10.1189/jlb.3a0513-242r
  91. Aguilar-Valenzuela Renan, Carlsen Eric D., Liang Yuejin, Soong Lynn, Sun Jiaren, Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity : Hepatocyte growth factor in hepatitis, 10.1111/jgh.12456
  92. Adams D. H., Harvath L., Bottaro D. P., Interrante R., Catalano G., Tanaka Y., Strain A., Hubscher S. G., Shaw S., Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells., 10.1073/pnas.91.15.7144
  93. Skibinski G., Skibinska A., James K., The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs, 10.1046/j.1365-2567.2001.01186.x
  94. Di Nicola M., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, 10.1182/blood.v99.10.3838
  95. Tamura, Sugawara, Tokoro, Taniguchi, Fukao, Nakauchi, Takahama, Expression and Function of c-Met, a Receptor for Hepatocyte Growth Factor, During T-Cell Development, 10.1046/j.1365-3083.1998.00324.x
  96. Komarowska Izabela, Coe David, Wang Guosu, Haas Robert, Mauro Claudio, Kishore Madhav, Cooper Dianne, Nadkarni Suchita, Fu Hongmei, Steinbruchel Daniel A., Pitzalis Costantino, Anderson Graham, Bucy Pat, Lombardi Giovanna, Breckenridge Ross, Marelli-Berg Federica M., Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release, 10.1016/j.immuni.2015.05.014
  97. Beilmann M, Blood, 90, 4450 (1997)
  98. Moransard M, Glia, 58, 559 (2010)
  99. Zhao Lan, Wu Yan, Xie Xu-Dong, Chu Yi-Fan, Li Jin-Qing, Zheng Limin, c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma : c-Met expression on activated monocytes in peritumoural stroma of HCC, 10.1002/path.4578
  100. Beilmann M, Blood, 95, 3964 (2000)
  101. Santoro Armando, Rimassa Lorenza, Borbath Ivan, Daniele Bruno, Salvagni Stefania, Van Laethem Jean Luc, Van Vlierberghe Hans, Trojan Jörg, Kolligs Frank T, Weiss Alan, Miles Steven, Gasbarrini Antonio, Lencioni Monica, Cicalese Luca, Sherman Morris, Gridelli Cesare, Buggisch Peter, Gerken Guido, Schmid Roland M, Boni Corrado, Personeni Nicola, Hassoun Ziad, Abbadessa Giovanni, Schwartz Brian, Von Roemeling Reinhard, Lamar Maria E, Chen Yinpu, Porta Camillo, Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, 10.1016/s1470-2045(12)70490-4
  102. Coudriet Gina M., He Jing, Trucco Massimo, Mars Wendy M., Piganelli Jon D., Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases, 10.1371/journal.pone.0015384
  103. Baek J.-H., Birchmeier C., Zenke M., Hieronymus T., The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity, 10.4049/jimmunol.1200729
  104. FALENTA K., RODAWAY A., JONES G.E., WELLS C.M., Imaging haematopoietic cells recruitment to an acute woundin vivoidentifies a role for c-Met signalling : C-MET INHIBITION AND WOUND RESPONSE, 10.1111/jmi.12035
  105. Jiang W, Immunology, 77, 147 (1992)
  106. Mine S, Lab Invest, 78, 1395 (1998)
  107. Granot Zvi, Henke Erik, Comen Elizabeth A., King Tari A., Norton Larry, Benezra Robert, Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung, 10.1016/j.ccr.2011.08.012
  108. Sagiv Jitka Y., Michaeli Janna, Assi Simaan, Mishalian Inbal, Kisos Hen, Levy Liran, Damti Pazzit, Lumbroso Delphine, Polyansky Lola, Sionov Ronit V., Ariel Amiram, Hovav Avi-Hai, Henke Erik, Fridlender Zvi G., Granot Zvi, Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer, 10.1016/j.celrep.2014.12.039
  109. Coffelt Seth B., Kersten Kelly, Doornebal Chris W., Weiden Jorieke, Vrijland Kim, Hau Cheei-Sing, Verstegen Niels J. M., Ciampricotti Metamia, Hawinkels Lukas J. A. C., Jonkers Jos, de Visser Karin E., IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis, 10.1038/nature14282
  110. Wculek Stefanie K., Malanchi Ilaria, Neutrophils support lung colonization of metastasis-initiating breast cancer cells, 10.1038/nature16140
  111. Fridlender Zvi G., Sun Jing, Kim Samuel, Kapoor Veena, Cheng Guanjun, Ling Leona, Worthen G. Scott, Albelda Steven M., Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN, 10.1016/j.ccr.2009.06.017
  112. Harrison Phillip, Bradley Lara, Bomford Adrian, Mechanism of Regulation of HGF/SF Gene Expression in Fibroblasts by TGF-β1, 10.1006/bbrc.2000.2612
  113. Mungunsukh O., Day R. M., Transforming growth factor- 1 selectively inhibits hepatocyte growth factor expression via a micro-RNA-199-dependent posttranscriptional mechanism, 10.1091/mbc.e13-01-0017
  114. Vodovotz Y., Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta, 10.1084/jem.178.2.605
  115. Parikh RA, Onco Targets Ther, 7, 969 (2014)
  116. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio P M, Giordano S, Silencing the MET oncogene leads to regression of experimental tumors and metastases, 10.1038/sj.onc.1210697
  117. Scagliotti G. V., Di Maio M., Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET…: Table 1., 10.1093/annonc/mdv334
  118. Garber Ken, MET inhibitors start on road to recovery, 10.1038/nrd4406
  119. Iveson Timothy, Donehower Ross C, Davidenko Irina, Tjulandin Sergey, Deptala Andrzej, Harrison Mark, Nirni Somanath, Lakshmaiah Kuntegowdanahalli, Thomas Anne, Jiang Yizhou, Zhu Min, Tang Rui, Anderson Abraham, Dubey Sarita, Oliner Kelly S, Loh Elwyn, Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study, 10.1016/s1470-2045(14)70023-3
  120. Haber Daniel A., Gray Nathanael S., Baselga Jose, The Evolving War on Cancer, 10.1016/j.cell.2011.03.026
  121. Lennerz Jochen K., Kwak Eunice L., Ackerman Allison, Michael Michael, Fox Stephen B., Bergethon Kristin, Lauwers Gregory Y., Christensen James G., Wilner Keith D., Haber Daniel A., Salgia Ravi, Bang Yung-Jue, Clark Jeffrey W., Solomon Benjamin J., Iafrate A. John, METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib, 10.1200/jco.2011.35.4928
  122. Choueiri Toni K., Vaishampayan Ulka, Rosenberg Jonathan E., Logan Theodore F., Harzstark Andrea L., Bukowski Ronald M., Rini Brian I., Srinivas Sandy, Stein Mark N., Adams Laurel M., Ottesen Lone H., Laubscher Kevin H., Sherman Laurie, McDermott David F., Haas Naomi B., Flaherty Keith T., Ross Robert, Eisenberg Peter, Meltzer Paul S., Merino Maria J., Bottaro Donald P., Linehan W. Marston, Srinivasan Ramaprasad, Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma, 10.1200/jco.2012.43.3383
  123. Abken Hinrich, Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors, 10.2217/imt.15.15
  124. Feldman Steven A., Assadipour Yasmine, Kriley Isaac, Goff Stephanie L., Rosenberg Steven A., Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors, 10.1053/j.seminoncol.2015.05.005
  125. Jensen Michael C, Riddell Stanley R, Designing chimeric antigen receptors to effectively and safely target tumors, 10.1016/j.coi.2015.01.002
  126. Rosenberg Steven A., Restifo Nicholas P., Yang James C., Morgan Richard A., Dudley Mark E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy, 10.1038/nrc2355
  127. Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C, A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity, 10.1038/onc.2013.245
  128. Kontermann Roland E., Brinkmann Ulrich, Bispecific antibodies, 10.1016/j.drudis.2015.02.008
  129. Yoshioka H., Azuma K., Yamamoto N., Takahashi T., Nishio M., Katakami N., Ahn M. J., Hirashima T., Maemondo M., Kim S. W., Kurosaki M., Akinaga S., Park K., Tsai C. M., Tamura T., Mitsudomi T., Nakagawa K., A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study), 10.1093/annonc/mdv288
  130. Tolaney Sara M., Tan Sally, Guo Hao, Barry William, Van Allen Eliezer, Wagle Nikhil, Brock Jane, Larrabee Katherine, Paweletz Cloud, Ivanova Elena, Janne Pasi, Overmoyer Beth, Wright John J., Shapiro Geoffrey I., Winer Eric P., Krop Ian E., Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer, 10.1007/s10637-015-0269-8
  131. Rutella S., Tolerogenic dendritic cells: cytokine modulation comes of age, 10.1182/blood-2006-03-006403
  132. Rosen L. S., Senzer N., Mekhail T., Ganapathi R., Chai F., Savage R. E., Waghorne C., Abbadessa G., Schwartz B., Dreicer R., A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors, 10.1158/1078-0432.ccr-11-1002
  133. Yap Timothy A., Olmos David, Brunetto Andre T., Tunariu Nina, Barriuso Jorge, Riisnaes Ruth, Pope Lorna, Clark Jeremy, Futreal Andrew, Germuska Michael, Collins David, deSouza Nandita M., Leach Martin O., Savage Ronald E., Waghorne Carol, Chai Feng, Garmey Edward, Schwartz Brian, Kaye Stan B., de Bono Johann S., Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies, 10.1200/jco.2010.31.0367
  134. Goldman Jonathan W., Laux Isett, Chai Feng, Savage Ronald E., Ferrari Dora, Garmey Edward G., Just Richard G., Rosen Lee S., Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib, 10.1002/cncr.27575
  135. Pant S., Saleh M., Bendell J., Infante J. R., Jones S., Kurkjian C. D., Moore K. M., Kazakin J., Abbadessa G., Wang Y., Chen Y., Schwartz B., Camacho L. H., A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors, 10.1093/annonc/mdu157
  136. Zucali PA, J Clin Oncol, 33, 2549 (2015)
  137. Sequist Lecia V., von Pawel Joachim, Garmey Edward G., Akerley Wallace L., Brugger Wolfram, Ferrari Dora, Chen Yinpu, Costa Daniel B., Gerber David E., Orlov Sergey, Ramlau Rodryg, Arthur Susan, Gorbachevsky Igor, Schwartz Brian, Schiller Joan H., Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer, 10.1200/jco.2010.34.0570
  138. Feldman Darren R., Einhorn Lawrence H., Quinn David I., Loriot Yohann, Joffe Johnathan K., Vaughn David J., Fléchon Aude, Hajdenberg Julio, Halim Abdel-Baset, Zahir Hamim, Motzer Robert J., A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors, 10.1007/s10637-013-9934-y
  139. Kang Yoon-Koo, Muro Kei, Ryu Min-Hee, Yasui Hirofumi, Nishina Tomohiro, Ryoo Baek-Yeol, Kamiya Yukimasa, Akinaga Shiro, Boku Narikazu, A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer, 10.1007/s10637-013-0057-2
  140. Pant S, J Clin Oncol, 33, 4065 (2015)
  141. Twardowski P, J Clin Oncol, 33, 4523 (2015)
  142. Vokes EE, J Clin Oncol, 33, 6060 (2015)
  143. Monk Bradley J., Miller David S., Tewari Krishnansu S., Reply to W.A.A. Tjalma and J.S. Grossman, 10.1200/jco.2014.59.6205
  144. Hirashima T, J Clin Oncol, 32, 8052 (2014)
  145. Lolkema M. P., Bohets H. H., Arkenau H.-T., Lampo A., Barale E., de Jonge M. J. A., van Doorn L., Hellemans P., de Bono J. S., Eskens F. A. L. M., The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation, 10.1158/1078-0432.ccr-14-3258
  146. McCoach CE, J Clin Oncol, 33, 2587 (2015)
  147. Bang Y-J, J Clin Oncol, 32, 2520 (2014)
  148. Hong DS, J Clin Oncol, 32, 2508 (2014)
  149. Sparano Joseph A., Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story, 10.1200/jco.2014.57.7890
  150. Jhaveri Komal, Ulaner Gary A., Dickler Maura N., Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This “Early Metabolic Look” Strategy?, 10.1200/jco.2015.62.3082
  151. Hong David S., Rosen Peter, Lockhart A. Craig, Fu Siqing, Janku Filip, Kurzrock Razelle, Khan Rabia, Amore Benny, Caudillo Isaac, Deng Hongjie, Hwang Yuying C., Loberg Robert, Ngarmchamnanrith Gataree, Beaupre Darrin M., Lee Peter, A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors, 10.18632/oncotarget.4472
  152. Gan HK, J Clin Oncol, 32, 11111 (2014)
  153. Salgia R., Patel P., Bothos J., Yu W., Eppler S., Hegde P., Bai S., Kaur S., Nijem I., Catenacci D. V. T., Peterson A., Ratain M. J., Polite B., Mehnert J. M., Moss R. A., Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies, 10.1158/1078-0432.ccr-13-2070
  154. Koeppen H., Yu W., Zha J., Pandita A., Penuel E., Rangell L., Raja R., Mohan S., Patel R., Desai R., Fu L., Do A., Parab V., Xia X., Januario T., Louie S. G., Filvaroff E., Shames D. S., Wistuba I., Lipkind M., Huang J., Lazarov M., Ramakrishnan V., Amler L., Phan S.-C., Patel P., Peterson A., Yauch R. L., Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib   Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit, 10.1158/1078-0432.ccr-13-1836
  155. Diéras V., Campone M., Yardley D. A., Romieu G., Valero V., Isakoff S. J., Koeppen H., Wilson T. R., Xiao Y., Shames D. S., Mocci S., Chen M., Schmid P., Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer, 10.1093/annonc/mdv263
  156. Cloughesy TF, J Clin Oncol, 33, 2015 (2015)
  157. Shah Manish A., Cho Jae Yong, Huat Iain Tan Bee, Tebbutt Niall C., Yen Chia-Jui, Kang Alice, Shames David S., Bu Lilian, Kang Yoon-Koo, Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC)., 10.1200/jco.2015.33.3_suppl.2
  158. Bendell Johanna C., Hochster Howard S., Hart Lowell L., Firdaus Irfan, Mace Joseph Ronald, McFarlane Joshua Jemison, Kozloff Mark, Catenacci Daniel Virgil Thomas, Hsu Jessie J., Hack Stephen Paul, Shames David S., Phan See-Chun, Cohn Allen Lee, A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC)., 10.1200/jco.2015.33.3_suppl.663
  159. Spigel David Robert, Peterson Amy Christian, Reply to A. Soultati et al, 10.1200/jco.2013.54.9683
  160. Shah MA, J Clin Oncol, vol. 33, 4012 (2015)
  161. Aftimos PG, J Clin Oncol, 33, 2580 (2015)
  162. Strickler JH, J Clin Oncol, 32, 2507 (2014)
  163. Kang Yoon-Koo, LoRusso Patricia, Salgia Ravi, Yen Chia-Jui, Lin Chia-Chi, Ramanathan Ramesh K., Kaminker Patrick, Sokolova Irina, Bhathena Anahita, Wang Lan, Naumovski Louie, Strickler John H., Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC)., 10.1200/jco.2015.33.3_suppl.167
  164. Tabernero J., Elez M. E., Herranz M., Rico I., Prudkin L., Andreu J., Mateos J., Carreras M. J., Han M., Gifford J., Credi M., Yin W., Agarwal S., Komarnitsky P., Baselga J., A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases, 10.1158/1078-0432.ccr-13-1837
  165. Patnaik A, Weiss G J, Papadopoulos K P, Hofmeister C C, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo F C, Cotreau M M, Ramanathan R K, Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma, 10.1038/bjc.2014.290